Sunshine Biopharma Inc
SBFM1.310USD
0.000
收盤 12/24, 13:00（美東）報價延遲15分鐘
5.97M總市值
0.25本益比TTM
關於 Sunshine Biopharma Inc 公司
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Sunshine Biopharma Inc簡介
公司代碼SBFM
公司名稱Sunshine Biopharma Inc
上市日期Aug 15, 2008
CEOSlilaty (Steve N)
員工數量52
證券類型Ordinary Share
年結日Aug 15
公司地址333 Las Olas Way
城市FORT LAUDERDALE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編33301
電話19543300684
網址https://www.sunshinebiopharma.com/
公司代碼SBFM
上市日期Aug 15, 2008
CEOSlilaty (Steve N)
Sunshine Biopharma Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Operating Officer, Director
Chief Operating Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Operating Officer, Director
Chief Operating Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月20日 週四
更新時間: 11月20日 週四
持股股東
股東類型
持股股東
持股股東
佔比
L1 Global Manager Pty Limited
2.90%
Citadel Advisors LLC
1.59%
Renaissance Technologies LLC
1.14%
DRW Securities, LLC
0.92%
Two Sigma Investments, LP
0.79%
其他
92.67%
持股股東
持股股東
佔比
L1 Global Manager Pty Limited
2.90%
Citadel Advisors LLC
1.59%
Renaissance Technologies LLC
1.14%
DRW Securities, LLC
0.92%
Two Sigma Investments, LP
0.79%
其他
92.67%
股東類型
持股股東
佔比
Investment Advisor
3.90%
Hedge Fund
3.51%
Research Firm
0.10%
Individual Investor
0.04%
其他
92.44%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
33
128.14K
2.61%
-276.56K
2025Q2
40
174.71K
3.84%
-217.75K
2025Q1
40
223.71K
4.97%
+181.45K
2024Q4
39
166.72K
8.34%
+112.42K
2024Q3
38
41.53K
13.09%
+24.77K
2024Q2
37
17.39K
14.86%
+11.35K
2024Q1
40
9.43K
19.69%
+5.56K
2023Q4
38
3.43K
26.72%
+270.00
2023Q3
34
2.71K
21.06%
-1.08K
2023Q2
34
3.32K
29.59%
+626.00
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Citadel Advisors LLC
63.43K
1.39%
+63.43K
--
Jun 30, 2025
Renaissance Technologies LLC
54.09K
1.19%
+54.09K
--
Jun 30, 2025
SBI Securities Co., Ltd.
6.69K
0.15%
+1.47K
+28.16%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
3.83K
0.08%
--
--
Jun 30, 2025
Chamoun (Malek)
1.85K
0.04%
--
--
Apr 01, 2025
UBS Financial Services, Inc.
206.00
0%
-19.68K
-98.96%
Jun 30, 2025
Osaic Holdings, Inc.
152.00
0%
+150.00
+7500.00%
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
公告日期
類型
比率
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
常見問題
Sunshine Biopharma Inc的前五大股東是誰？
Sunshine Biopharma Inc的前五大股東如下：
Citadel Advisors LLC持有股份：63.43K佔總股份比例：1.39%。
Renaissance Technologies LLC持有股份：54.09K佔總股份比例：1.19%。
SBI Securities Co., Ltd.持有股份：6.69K佔總股份比例：0.15%。
Morgan Stanley Smith Barney LLC持有股份：3.83K佔總股份比例：0.08%。
Chamoun (Malek)持有股份：1.85K佔總股份比例：0.04%。
Citadel Advisors LLC持有股份：63.43K佔總股份比例：1.39%。
Renaissance Technologies LLC持有股份：54.09K佔總股份比例：1.19%。
SBI Securities Co., Ltd.持有股份：6.69K佔總股份比例：0.15%。
Morgan Stanley Smith Barney LLC持有股份：3.83K佔總股份比例：0.08%。
Chamoun (Malek)持有股份：1.85K佔總股份比例：0.04%。
Sunshine Biopharma Inc的前三大股東類型是什麼？
Sunshine Biopharma Inc 的前三大股東類型分別是：
L1 Global Manager Pty Limited
Citadel Advisors LLC
Renaissance Technologies LLC
L1 Global Manager Pty Limited
Citadel Advisors LLC
Renaissance Technologies LLC
有多少機構持有Sunshine Biopharma Inc(SBFM)的股份？
截至2025Q3，共有33家機構持有Sunshine Biopharma Inc的股份，合計持有的股份價值約為128.14K，占公司總股份的2.61% 。與2025Q2相比，機構持股有所增加，增幅為-1.22%。
哪個業務部門對Sunshine Biopharma Inc的收入貢獻最大？
在--，--業務部門對Sunshine Biopharma Inc的收入貢獻最大，創收--，占總收入的--% 。
